Atea Pharmaceuticals (AVIR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, with voting available online or virtually.
Shareholders are encouraged to review proxy materials and vote by June 17, 2026.
Voting matters and shareholder proposals
Election of three Class III directors: Jerome Adams, Howard Berman, and Barbara Duncan, with board recommending a vote in favor.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory (non-binding) approval of named executive officer compensation, with board recommending a vote in favor.
Provision for other business to be transacted as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election to Class III positions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Atea Pharmaceuticals
- BEM/RZR met Phase 3 endpoints, supporting NDA plans for HCV in 2027 and strong commercial prospects.AVIR
Q2 2026 - Director elections, clinical milestones, and strong financials marked the meeting's key outcomes.AVIR
AGM 2026 - Phase 3 HCV trials advance toward 2026 readouts as R&D drives higher net loss and cash supports runway.AVIR
Q1 2026 - Proxy covers director elections, auditor ratification, and performance-based executive pay.AVIR
Proxy filing - Phase III HCV and HEV programs advance, topline results in 2026, cash $301.8M, net loss $158.4M.AVIR
Q4 2025 - Late-stage HCV and preclinical HEV programs advance with strong clinical and market momentum.AVIR
44th Annual J.P. Morgan Healthcare Conference - HCV Phase 2 results due December; $482.8M cash funds operations through 2027.AVIR
Q3 2024 - Pivotal COVID-19 and HCV trial results due late 2024; $502.2M cash funds operations into 2027.AVIR
Q2 2024 - Strong phase II HCV results and a pivotal COVID-19 trial set up major milestones for late 2024.AVIR
Jefferies 2024 Global Healthcare Conference